Regado sinks on permanent Phase III Revolixys halt

Regado Biosciences's stock price plunged 60.2% to $1.13 per share on 25 August after the company announced a permanent stop to its Phase III REGULATE-PCI clinical trial for Revolixys (REG1), a factor IXa inhibitor combined with the anticoagulant's active control agent.